Table 1.

Efficacy of Clopidogrel Plus Aspirin in Selected Clinical Trials

TrialPatient PopulationEndpointEvent Rate Combination (%)Event Rate Monotherapy (%)P
CHARISMA (3)CADCV death, MI, or CVA at 28 months6.87.3.22
MATCH (5)CVACVA, MI, CV death, or CV hospitalization at 18 months15.716.7*.244
CLARITY (6)STEMIOcclusion, death, or recurrent MI at 8 days1521.7<.001
CURE (9)NSTEMICV death, MI, or CVA at 12 months9.311.4<.001
PCI-CURE (12)NSTEMI with PCICV death or MI at 8 months8.812.6.002
CREDO (11)PCIDeath, MI, or CVA at 12 months8.511.5.02
  • * Clopidogrel monotherapy.

  • CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; MATCH, Management of Atherothrombosis with Clopidogrel in High-Risk Patients; CLARITY, Clopidogrel as Adjunctive Reperfusion Therapy; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; PCI-CURE, Percutaneous Coronary Intervention in the Clopidogrel in Unstable Angina to Prevent Recurrent Events; CREDO, Clopidogrel for the Reduction of Events During Observation; CAD, coronary artery disease; CVA, cardiovascular accident; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CV, cardiovascular; MI, myocardial infarction.